Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing 100700, China; State Key Laboratory Breeding Base of Dao-di Herbs, National Resource Center for Chinese Materia Medica, Center for Post-doctoral Research, China Academy of Chinese Medical Sciences, Beijing 100700, China; State Key Laboratory of Generic Manufacture Technology of Traditional Chinese Medicine, Lunan Pharmaceutical Group Co. Ltd, Shandong 276006, China.
LU-European Center for Chinese Medicine and Natural Compounds, Institute of Biology, Leiden University, Sylviusweg 72, 2333 BE Leiden, the Netherlands.
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Aug 1;1179:122808. doi: 10.1016/j.jchromb.2021.122808. Epub 2021 May 27.
The World Health Organization has shown that coronary heart disease (CHD) is a more common cause of death than cancer. In traditional Chinese medicine (TCM), CHD is classified as a form of thoracic obstruction that can be divided in different subtypes including Qi stagnation with blood stasis (QS) and Qi deficiency with blood stasis (QD). Different treatment strategies are used based on this subtyping. Owing to the lack of scientific markers in the diagnosis of these subtypes, subjective judgments made by clinicians have limited the objective manner for utility of TCM in the treatment of CHD. Untargeted (UHPLC-QTOF-MS) and targeted (UHPLC-MS/MS) metabolomics approaches were employed to search significantly different metabolites related to the QS or QD subtypes of CHD with angina pectoris in this study. A total of 42 metabolites were obtained in the untargeted metabolomics analysis and 34 amino acids were detected in the targeted metabolomics analysis. In total, 16 metabolites were found significantly different among different groups. The results showed distinct metabolic profiles of urine samples not only between CHD patients and healthy controls, but also between the two subtypes of CHD. Pathway analysis of the significantly varied metabolites revealed that there were subtype-related differences in the activity of pathways. Therefore, urinary metabolomics can reveal the pathological changes of CHD in different subtypes, make the diagnosis of CHD in different subtypes in an objective manner and comprehensive and contribute to personalized treatment by providing scientific evidence.
世界卫生组织表明,冠心病(CHD)是比癌症更为常见的死因。在中医(TCM)中,CHD 被归类为胸痹的一种形式,可以分为不同亚型,包括气滞血瘀(QS)和气虚血瘀(QD)。根据这种亚型分类,采用不同的治疗策略。由于缺乏这些亚型诊断的科学标志物,临床医生的主观判断限制了 TCM 在 CHD 治疗中的客观应用。本研究采用非靶向(UHPLC-QTOF-MS)和靶向(UHPLC-MS/MS)代谢组学方法,寻找与 CHD 伴有胸痛的 QS 或 QD 亚型相关的差异显著的代谢物。在非靶向代谢组学分析中获得了 42 种代谢物,在靶向代谢组学分析中检测到 34 种氨基酸。总共发现 16 种代谢物在不同组之间存在显著差异。结果表明,CHD 患者和健康对照组之间,以及 CHD 的两种亚型之间,尿液样本的代谢谱存在明显差异。对差异代谢物进行途径分析表明,不同亚型的通路活性存在差异。因此,尿代谢组学可以揭示不同亚型 CHD 的病理变化,以客观和全面的方式对 CHD 进行不同亚型的诊断,并通过提供科学证据为个性化治疗做出贡献。